AGLE:NSD-Aeglea BioTherapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.56

Change

0.00 (0.00)%

Market Cap

USD 0.32B

Volume

0.08M

Avg Analyst Target

USD 12.00 (+82.93%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD140.07B 233.80 177.21
BNTX BioNTech SE

N/A

USD68.10B 51.40 36.74
REGN Regeneron Pharmaceuticals, Inc

N/A

USD62.47B 16.69 13.11
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD51.90B 19.11 12.98
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

N/A

USD29.28B N/A N/A
GMAB Genmab A/S

N/A

USD29.00B 33.07 3.64
SGEN Seagen Inc

N/A

USD26.42B 40.63 36.19
RPRX Royalty Pharma plc

N/A

USD24.49B 33.25 14.59
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD21.44B N/A N/A

ETFs Containing AGLE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.65% 45% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.65% 45% F 19% F
Trailing 12 Months  
Capital Gain -9.39% 49% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.39% 49% F 17% F
Trailing 5 Years  
Capital Gain 45.45% 61% D- 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.45% 61% D- 47% F
Average Annual (5 Year Horizon)  
Capital Gain 18.66% 53% F 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.66% 53% F 65% D
Risk Return Profile  
Volatility (Standard Deviation) 56.43% 55% F 31% F
Risk Adjusted Return 33.07% 59% F 50% F
Market Capitalization 0.32B 48% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.68 62% D- 51% F
Price / Cash Flow Ratio -4.24 33% F 63% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -96.52% 26% F 19% F
Return on Invested Capital -81.52% 25% F 9% F
Return on Assets -44.15% 16% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.30 23% F 13% F
Short Percent 6.21% 53% F 32% F
Beta 1.63 36% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector